New HCC Index
Inflammatory indices are informative when it comes to the treatment outcomes in cancers. A number of inflammatory-based indices have been developed to prognose hepatocellular carcinoma (HCC). However, these indices were not specifically created for HCC and thus the findings lacked consistency across subgroups of patients. In the study “Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma”, it established a novel HCC-specific inflammatory score and validated its prognostic ability in both Eastern and Western population of HCC. The new index outperformed other inflammatory indices, having the best prognostic performances. Moreover, its performance was consistent across subgroups of patients with different tumour burden and lives dysfunction. (Liver Cancer. 2020 Apr;9(2):167-181. doi: 10.1159/000504252. Epub 2019 Nov 21.)
Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof Stephen CHAN in the Department of Clinical Oncology, CUHK. Prof Chan’s research focuses on hepatocellular carcinoma, pancreatic cancer, biliary tract cancer and neuroendocrine tumor.